FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048012259> ?p ?o ?g. }

• W3048012259 endingPage "411" @default.
• W3048012259 startingPage "402" @default.
• W3048012259 abstract "Background HIV-infection is associated with increased mortality during multidrug-resistant tuberculosis treatment, but the extent to which the use of antiretroviral therapy (ART) and anti-tuberculosis medications modify this risk are unclear. Our objective was to evaluate how use of these treatments altered mortality risk in HIV-positive adults with multidrug-resistant tuberculosis. Methods We did an individual patient data meta-analysis of adults 18 years or older with confirmed or presumed multidrug-resistant tuberculosis initiating tuberculosis treatment between 1993 and 2016. Data included ART use and anti-tuberculosis medications grouped according to WHO effectiveness categories. The primary analysis compared HIV-positive with HIV-negative patients in terms of death during multidrug-resistant tuberculosis treatment, excluding those lost to follow up, and was stratified by ART use. Analyses used logistic regression after exact matching on country World Bank income classification and drug resistance and propensity-score matching on age, sex, geographic site, year of multidrug-resistant tuberculosis treatment initiation, previous tuberculosis treatment, directly observed therapy, and acid-fast-bacilli smear-positivity to obtain adjusted odds ratios (aORs) and 95% CIs. Secondary analyses were conducted among those with HIV-infection. Findings We included 11 920 multidrug-resistant tuberculosis patients. 2997 (25%) were HIV-positive and on ART, 886 (7%) were HIV-positive and not on ART, and 1749 (15%) had extensively drug-resistant tuberculosis. By use of HIV-negative patients as reference, the aOR of death was 2·4 (95% CI 2·0–2·9) for all patients with HIV-infection, 1·8 (1·5–2·2) for HIV-positive patients on ART, and 4·2 (3·0–5·9) for HIV-positive patients with no or unknown ART. Among patients with HIV, use of at least one WHO Group A drug and specific use of moxifloxacin, levofloxacin, bedaquiline, or linezolid were associated with significantly decreased odds of death. Interpretation Use of ART and more effective anti-tuberculosis drugs is associated with lower odds of death among HIV-positive patients with multidrug-resistant tuberculosis. Access to these therapies should be urgently pursued. Funding American Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America. HIV-infection is associated with increased mortality during multidrug-resistant tuberculosis treatment, but the extent to which the use of antiretroviral therapy (ART) and anti-tuberculosis medications modify this risk are unclear. Our objective was to evaluate how use of these treatments altered mortality risk in HIV-positive adults with multidrug-resistant tuberculosis. We did an individual patient data meta-analysis of adults 18 years or older with confirmed or presumed multidrug-resistant tuberculosis initiating tuberculosis treatment between 1993 and 2016. Data included ART use and anti-tuberculosis medications grouped according to WHO effectiveness categories. The primary analysis compared HIV-positive with HIV-negative patients in terms of death during multidrug-resistant tuberculosis treatment, excluding those lost to follow up, and was stratified by ART use. Analyses used logistic regression after exact matching on country World Bank income classification and drug resistance and propensity-score matching on age, sex, geographic site, year of multidrug-resistant tuberculosis treatment initiation, previous tuberculosis treatment, directly observed therapy, and acid-fast-bacilli smear-positivity to obtain adjusted odds ratios (aORs) and 95% CIs. Secondary analyses were conducted among those with HIV-infection. We included 11 920 multidrug-resistant tuberculosis patients. 2997 (25%) were HIV-positive and on ART, 886 (7%) were HIV-positive and not on ART, and 1749 (15%) had extensively drug-resistant tuberculosis. By use of HIV-negative patients as reference, the aOR of death was 2·4 (95% CI 2·0–2·9) for all patients with HIV-infection, 1·8 (1·5–2·2) for HIV-positive patients on ART, and 4·2 (3·0–5·9) for HIV-positive patients with no or unknown ART. Among patients with HIV, use of at least one WHO Group A drug and specific use of moxifloxacin, levofloxacin, bedaquiline, or linezolid were associated with significantly decreased odds of death. Use of ART and more effective anti-tuberculosis drugs is associated with lower odds of death among HIV-positive patients with multidrug-resistant tuberculosis. Access to these therapies should be urgently pursued." @default.
• W3048012259 created "2020-08-13" @default.
• W3048012259 creator A5021479889 @default.
• W3048012259 creator A5021648205 @default.
• W3048012259 creator A5026340422 @default.
• W3048012259 creator A5047231006 @default.
• W3048012259 creator A5051230101 @default.
• W3048012259 creator A5051897048 @default.
• W3048012259 creator A5057051062 @default.
• W3048012259 creator A5057408967 @default.
• W3048012259 creator A5062454253 @default.
• W3048012259 creator A5063282541 @default.
• W3048012259 creator A5068645131 @default.
• W3048012259 creator A5070917839 @default.
• W3048012259 creator A5077926734 @default.
• W3048012259 creator A5080386236 @default.
• W3048012259 creator A5082446603 @default.
• W3048012259 creator A5084786927 @default.
• W3048012259 creator A5085134523 @default.
• W3048012259 date "2020-08-01" @default.
• W3048012259 modified "2023-10-13" @default.
• W3048012259 title "Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis" @default.
• W3048012259 cites W1872873119 @default.
• W3048012259 cites W2000759284 @default.
• W3048012259 cites W2034147497 @default.
• W3048012259 cites W2061273963 @default.
• W3048012259 cites W2064412293 @default.
• W3048012259 cites W2090076847 @default.
• W3048012259 cites W2091969879 @default.
• W3048012259 cites W2111887635 @default.
• W3048012259 cites W2117344292 @default.
• W3048012259 cites W2123717316 @default.
• W3048012259 cites W2140154490 @default.
• W3048012259 cites W2148389844 @default.
• W3048012259 cites W2151102304 @default.
• W3048012259 cites W2160571788 @default.
• W3048012259 cites W2163899436 @default.
• W3048012259 cites W2201196793 @default.
• W3048012259 cites W2231160946 @default.
• W3048012259 cites W2301803454 @default.
• W3048012259 cites W2780608268 @default.
• W3048012259 cites W2793264342 @default.
• W3048012259 cites W2859364562 @default.
• W3048012259 cites W2885449068 @default.
• W3048012259 cites W2888424515 @default.
• W3048012259 cites W2891690058 @default.
• W3048012259 cites W2969109607 @default.
• W3048012259 doi "https://doi.org/10.1016/s0140-6736(20)31316-7" @default.
• W3048012259 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8094110" @default.
• W3048012259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32771107" @default.
• W3048012259 hasPublicationYear "2020" @default.
• W3048012259 type Work @default.
• W3048012259 sameAs 3048012259 @default.
• W3048012259 citedByCount "43" @default.
• W3048012259 countsByYear W30480122592020 @default.
• W3048012259 countsByYear W30480122592021 @default.
• W3048012259 countsByYear W30480122592022 @default.
• W3048012259 countsByYear W30480122592023 @default.
• W3048012259 crossrefType "journal-article" @default.
• W3048012259 hasAuthorship W3048012259A5021479889 @default.
• W3048012259 hasAuthorship W3048012259A5021648205 @default.
• W3048012259 hasAuthorship W3048012259A5026340422 @default.
• W3048012259 hasAuthorship W3048012259A5047231006 @default.
• W3048012259 hasAuthorship W3048012259A5051230101 @default.
• W3048012259 hasAuthorship W3048012259A5051897048 @default.
• W3048012259 hasAuthorship W3048012259A5057051062 @default.
• W3048012259 hasAuthorship W3048012259A5057408967 @default.
• W3048012259 hasAuthorship W3048012259A5062454253 @default.
• W3048012259 hasAuthorship W3048012259A5063282541 @default.
• W3048012259 hasAuthorship W3048012259A5068645131 @default.
• W3048012259 hasAuthorship W3048012259A5070917839 @default.
• W3048012259 hasAuthorship W3048012259A5077926734 @default.
• W3048012259 hasAuthorship W3048012259A5080386236 @default.
• W3048012259 hasAuthorship W3048012259A5082446603 @default.
• W3048012259 hasAuthorship W3048012259A5084786927 @default.
• W3048012259 hasAuthorship W3048012259A5085134523 @default.
• W3048012259 hasBestOaLocation W30480122592 @default.
• W3048012259 hasConcept C114851261 @default.
• W3048012259 hasConcept C126322002 @default.
• W3048012259 hasConcept C133936738 @default.
• W3048012259 hasConcept C142724271 @default.
• W3048012259 hasConcept C156957248 @default.
• W3048012259 hasConcept C203014093 @default.
• W3048012259 hasConcept C2777107064 @default.
• W3048012259 hasConcept C2777975735 @default.
• W3048012259 hasConcept C2781069245 @default.
• W3048012259 hasConcept C71924100 @default.
• W3048012259 hasConcept C86803240 @default.
• W3048012259 hasConcept C89423630 @default.
• W3048012259 hasConceptScore W3048012259C114851261 @default.
• W3048012259 hasConceptScore W3048012259C126322002 @default.
• W3048012259 hasConceptScore W3048012259C133936738 @default.
• W3048012259 hasConceptScore W3048012259C142724271 @default.
• W3048012259 hasConceptScore W3048012259C156957248 @default.
• W3048012259 hasConceptScore W3048012259C203014093 @default.
• W3048012259 hasConceptScore W3048012259C2777107064 @default.
• W3048012259 hasConceptScore W3048012259C2777975735 @default.
• W3048012259 hasConceptScore W3048012259C2781069245 @default.

• next